antihemophilic factor viii (Recombinant), Fc-fusion protein (Eloctate) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA
AACT DrugBank Drug Central KEGG MeSH

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

Alternative names

antihemophilic factor (recombinant bdd), fc fusion protein | antihemophilic factor (recombinant, fc fusion protein) | antihemophilic factor (recombinant), fc fusion protein | biib031 | coagulation factor viii recombinant immunoglubulin g1 fusion protein | efmoroctocog alfa | efraloctocog alfa | elocta | eloctate | factor viii fc fusion protein | factor viii-fc fusion protein | rfviiifc protein

Organizations (15)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Hemophilia A

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Factor VIII (Phase 4)

Hemophilia A (Phase 4)

Menstruation Disturbances (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 21
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue